IRIS
RUZZO, ANNAMARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.017
EU - Europa 6.839
AS - Asia 3.131
OC - Oceania 37
AF - Africa 20
SA - Sud America 17
Continente sconosciuto - Info sul continente non disponibili 16
AN - Antartide 1
Totale 21.078
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.963
GB - Regno Unito 2.461
CN - Cina 2.055
UA - Ucraina 1.202
IT - Italia 773
TR - Turchia 509
FR - Francia 491
SE - Svezia 486
DE - Germania 371
FI - Finlandia 370
SG - Singapore 329
IE - Irlanda 239
RU - Federazione Russa 203
PL - Polonia 97
IN - India 68
AT - Austria 62
KR - Corea 57
CA - Canada 47
AU - Australia 32
BE - Belgio 25
NL - Olanda 21
IR - Iran 17
EU - Europa 15
JP - Giappone 15
PK - Pakistan 15
HK - Hong Kong 11
VN - Vietnam 9
RO - Romania 8
TG - Togo 7
BG - Bulgaria 6
BR - Brasile 6
SA - Arabia Saudita 6
EG - Egitto 5
NZ - Nuova Zelanda 5
BD - Bangladesh 4
EC - Ecuador 4
ID - Indonesia 4
JO - Giordania 4
MX - Messico 4
CZ - Repubblica Ceca 3
ES - Italia 3
GR - Grecia 3
IQ - Iraq 3
LK - Sri Lanka 3
MA - Marocco 3
TH - Thailandia 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BH - Bahrain 2
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
DK - Danimarca 2
HU - Ungheria 2
KZ - Kazakistan 2
MO - Macao, regione amministrativa speciale della Cina 2
PA - Panama 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CU - Cuba 1
CY - Cipro 1
GS - Georgia del Sud e Isole Sandwich Australi 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LT - Lituania 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
PH - Filippine 1
SI - Slovenia 1
Totale 21.078
Salva come PNG Salva come JPEG
Città #
Southend 2.274
Fairfield 1.665
Woodbridge 1.291
Houston 1.156
Jacksonville 963
Ashburn 822
Seattle 713
Ann Arbor 679
Cambridge 670
Wilmington 645
Nanjing 606
Chandler 515
Izmir 400
Singapore 280
Boardman 243
Dublin 239
Nanchang 215
Beijing 179
Helsinki 145
Princeton 144
Bremen 135
New York 111
Shenyang 105
San Mateo 101
Kunming 98
Tianjin 98
Hebei 90
Kraków 90
Urbino 88
Jiaxing 71
Istanbul 69
San Diego 67
Moscow 66
Changsha 63
Düsseldorf 62
Vienna 61
Hangzhou 48
Seongnam 44
Velikiy Novgorod 42
Shanghai 41
Guangzhou 40
London 39
Jinan 34
San Francisco 34
Toronto 32
Falls Church 29
Munich 27
Ningbo 27
Lanzhou 26
Changchun 24
Santa Clara 23
Strasbourg 23
Rome 20
Ancona 19
Dearborn 19
Brussels 18
Los Angeles 18
Zhengzhou 18
Mülheim 15
Redwood City 15
Taizhou 14
Acton 13
Melbourne 13
Milan 12
Pesaro 12
Bisceglie 11
Norwalk 11
Cesena 10
Indiana 10
Kocaeli 10
Turin 10
Auburn Hills 9
Cagliari 9
Canberra 9
Fuzhou 9
Hefei 9
Multan 9
Wuhan 9
Augusta 8
Chicago 8
Monterotondo 8
Paris 8
Des Moines 7
Fano 7
Haikou 7
Lomé 7
Portland 7
Tappahannock 7
Tokyo 7
Bangalore 6
Ottawa 6
Perugia 6
Riyadh 6
Saint Petersburg 6
Seoul 6
Shenzhen 6
Tortolì 6
Amsterdam 5
Bologna 5
Chiswick 5
Totale 16.227
Salva come PNG Salva come JPEG
Nome #
TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 267
XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT 264
2196 Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts) 263
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 235
C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC). 233
The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome 229
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients 228
Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial 226
Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of diffuse gastric cancer patients. 215
VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 215
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 209
Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy 206
Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC) 199
Evaluation of MET using FISH, IHC, or mass spectrometry as a prognostic biomarker in patients with gastroesophageal cancer 198
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. 195
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients 192
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes 191
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 191
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC) 190
Structure of the human hexokinase type I gene and nucleotide sequence of the 5' flanking region 189
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients 189
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. 189
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan 188
Genetic modulation of the Interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy 186
Effect of polymorphisms and miRNAs targeting CLOCK gene on gender-related survival in metastatic colorectal cancer (mCRC) patients (pts). 185
The genotype of a new linked DNA marker, MP6d-9, is related to the clinicalcourse of cystic fibrosis. 184
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. 183
MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC) 183
NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population 181
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 180
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. 179
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer 176
Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy 175
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district. 174
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 173
Evaluation of Period 2 gene (PER-2) biologic profile in advanced colorectal cancer (ACC) patients treated with chronomodulated chemotherapy 173
The G/A Nucleotide Change at cDNA Position 2494 in the E-Cadherin Gene (CDH1): Analysis in Italian Patients 172
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. 172
High resolution melting (HRM) analysis for the detection of ER22/23EK, BclI, and N363S polymorphisms of the glucocorticoid receptor gene. 170
Emerging biomarkers in bladder cancer identified by network analysis of transcriptomic data 170
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy 169
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. 169
BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (mCRC) PATIENTS 169
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in italian population 168
An erythroid-specific exon is present in the human hexokinase gene 168
Glucose metabolism enzymes gene expression analysis and selective metabolism advantage in the clinical progression of colorectal cancer (CRC) 168
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 167
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? 166
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. 166
PTEN EXPRESSION AND KRAS MUTATIONS AS PREDICTORS OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 165
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy 163
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer 163
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition 162
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district 161
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 161
Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization 160
A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4 159
Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients 159
Association of Thymidylate Synthase Polymorphisms with Gastric Cancer Susceptibility 158
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer 157
High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease 157
K-RAS STATUS IN PRIMARY COLORECTAL TUMOURS CORRELATE WITH K-RAS STATUS IN RELATED METASTATIC SITES: IMPLICATIONS FOR TREATMENT WITH ANTI-EGFR ANTIBODIES IN CLINICAL SETTING 154
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer 153
THE EXPRESSION OF THE KRAS mRNA ISOFORMS 4A AND 4B IN PLASMA: A COMPARISON BETWEEN LUNG ADENOCARCINOMA PATIENTS AND HEALTHY DONORS THROUGH LIQUID BIOPSY 152
Structure of the 5' region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA 150
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice 149
Hexokinase 149
PHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA TRIAL 149
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs 147
Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. 146
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk italian population 145
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice 145
XRCC1 399GG GENOTYPE PREDICTS SIGNIFICANTLY LONGER OVERALL SURVIVAL AND LONG LASTING CR IN RESISTANT LYMPHOMA TREATED WITH BENDA-BEAM AND ASCT 145
Structure of the human hexokinase type I gene. 145
Amplificazione enzimatica specifica di una regione di DNA strettamente associata alla Corea di Huntington 144
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patientstreated with surgery and adjuvant chemotherapy. 143
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 142
Pharmacogenetic profiling for toxicity of oxaliplatin and fluoripyrimidines. An Ancillary protocol to the TOSCA trial 142
Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy 141
Period 2 (PER-2) biologic profile in advanced colorectal cancer (ACC) patients (pts) 141
Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR 141
Sex-Related Differences in Impact On Safety Of Pharmacogenetic Profile For Colon Cancer Patients Treated With FOLFOX-4 or XELOX Adjuvant Chemotherapy 141
Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer 141
Linkage disequilibrium for DNA haplotypes near the cystic fibrosis locus in twosouth European populations 140
Glucose-6-phosphate dehydrogenase nucleotide 1311 polymorphism in central Italy(Marche Region). 140
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomized, phase III adjuvant TOSCA trial in high-risk colon cancer patients. 139
TS, MTHFR AND XRCC1 GENETIC VARIANTS AFFECT THE CLINICAL COURSE OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 138
TP53 mutation analysis in gastric cancer and clinical outcomes of patients with metastatic disease treated with Ramucirumab-Paclitaxel or standard chemotherapy 138
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients 136
Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial 136
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma 136
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy 135
Molecular basis of the 2',3'-dideoxycytidine induced drug-resistance in human cells 134
Prognostic role of thymidylate synthase (TS) gene polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. 132
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. 131
BRAF mutations and EGFR Intron-1 L/L genotype are associated with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 129
HOST GENETIC VARIANTS IN THE INSULIN GROWTH FACTOR BINDING PROTEIN-3 IMPACT ON SURVIVAL OF PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH PALLIATIVE CHEMOTHERAPY 129
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer 128
Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells. 127
Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. 126
Totale 16.831
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.966
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.966
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.785 0 0 0 0 0 0 480 399 288 293 151 174
2020/20212.888 117 260 282 243 247 219 284 200 370 224 349 93
2021/20221.753 116 188 210 223 82 69 76 95 107 84 81 422
2022/20231.954 286 78 22 201 252 413 7 103 360 70 96 66
2023/2024650 68 52 33 46 82 161 26 45 8 56 7 66
2024/20251.132 116 87 474 146 75 233 1 0 0 0 0 0
Totale 21.376